Anke Bio: Sales target for trastuzumab in 2026 remains focused on significant growth in revenue and profit

MetaMuskRat · 2026-04-03T04:52:03+00:00

Anke Bio stated during the conference call that its trastuzumab "Anstine" is expected to be approved for market launch by the end of 2023, with sales revenue increasing by 108.33% in 2025. The company will actively promote market expansion and plans to significantly increase revenue and profit by 2026.

MetaMuskRat

2026-04-03 04:52:03

Abstract generation in progress

People’s Finance and News, April 2—On a conference call, Sinobiotech (300009) said that its trastuzumab “Ansettin” was approved for listing at the end of 2023. In 2025, sales revenue increased 108.33% year over year, with rapid growth, and it has already achieved profitability for that single product. After the relevant policies take effect in 2026, if in 2026 this product is not included in the national centralized drug procurement, the company will further and more actively advance its market layout for this product; if the product is included in the national centralized drug procurement as a domestic alternative, as a late entrant the company will benefit significantly. In 2026, the company’s sales target for its trastuzumab remains a strong double-digit increase in both revenue and profit.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.